Notably, normal prostate epithelial cells (expressing high levels of BRCA2) and BRCA2-defective castration-resistant prostate cancer cells are resistant to the two analogues, indicating that the mechanism involved in 2-N-6-BP- and 2,6-DTP-mediated apoptosis is effective only in cancer cells and requires BRCA2. The gene discussed is BRCA2; the disease is prostate carcinoma.